MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Intermediaries
Private Equity, Investment Banking, Financial Services, Factoring
Analysts, Investment Banks: Top Performing Recommendations & Analysis
Finance & Acquisitions: BAKER BROTHERS ADVISORS LP
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)*
Organization & Developments: Rhythm Pharma
Uniqure NV
(NASDAQ: QURE)
Parents
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)*
Children
*Biotechnology company is developing therapies against metabolic diseases, such as diabetes.
*The Boston-based startup is expected to use the proceeds to fund the clinical trials of its experimental peptide-based drugs, in
2012: Rhythm Drums Up $25M Series B to Advance Diabetes and Obesity Drugs (2012)
2017: Orphan Disease IPO, Rhythm Pharmaceuticals: Initiating Coverage With Buy Rating And $34 Price Target (40% Upside) - Rhythm Pharmaceuticals (Pending:RYTM)
2017: Rhythm Pharmaceuticals: Today's Data Is Just The Beginning_seekingalpha
2019: Rhythm Pharma: Investible Based On Upcoming Trial Data _ seekingalpha.com
2019: Rhythm Pharmaceuticals And Setmelanotide In Rare Obesity_seekingalpha.com
2019: Rhythm Pharmaceuticals: Opportunity To Take Position Ahead Of Pivotal Data_seekingalpha.com
2020: Rhythm Pharma Announces FDA Approval Of IMCIVREE - Quick Facts_nasdaq
2021: Potentially Time To Fatten Up On Rhythm Pharmaceuticals
2022: Rhythm Pharma: An Incremental Approach Works Well For Setmelanotide_ seekingalpha.com
2022: Rhythm Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Rhythm Pharmaceuticals: Revisiting The Investment Thesis_ seekingalpha.com
2023: Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specialist_ seekingalpha.com
2024: A Glimpse Into The Expert Outlook On Rhythm Pharmaceuticals Through 13 Analysts
2024: Rhythm Pharmaceuticals Announces ▼ IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency to include Children as Young as 2 Years Old
2024: Rhythm Pharmaceuticals: A Key Year Ahead
2024: Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck
2025: Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven_ seekingalpha.com
Jumps
*Key People: Rhythm Pharma
Finance & Acquisitions: Rhythm Pharma